SCHEMBL1887253

SCHEMBL1887253

Fc1cnc2ncsc2c1

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31
HSD17B10 Q99714 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
LTA4H P09960 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9903909 0.75 GRM5 (0.40)
SCHEMBL21958562 0.74 DAO (0.32) ALDH1A1HSD17B10NPC1RAB9A
SCHEMBL1892905 0.74 HSD17B10 (0.34) ALDH1A1HSD17B10NPC1RAB9ALTA4H
SCHEMBL5751246 0.74 ALDH1A1 (0.31) ALDH1A1HSD17B10
SCHEMBL1892659 0.74 KDM4E (0.46) ALDH1A1HSD17B10
SCHEMBL9902755 0.74 DYRK1A (0.39) ALDH1A1HSD17B10NPC1RAB9A
SCHEMBL9903573 0.74 GRM5 (0.39) NPC1RAB9A
SCHEMBL23872468 0.71 NPC1 (0.35) NPC1RAB9A
SCHEMBL17901837 0.71 DAO (0.31) NPC1RAB9A
SCHEMBL9902877 0.70 GRM5 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190503-A1 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICAL NV 2011-08-04 US disclosed
US-20110159563-A1 Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICAL NV 2011-06-30 US disclosed
US-7939527-B2 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICA NV (BE) 2011-05-10 US disclosed
US-20090258854-A1 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase JANSSEN PHARMACEUTICA NV (BE) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258854-A1 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase LTA4H, LTC4S, LTB4R2 ALDH1A1 859/4885HSD17B10 664/4885NPC1 1359/4885
US-20110159563-A1 Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase LTA4H, LTC4S, LTB4R2 ALDH1A1 816/4885HSD17B10 1003/4885NPC1 2073/4885
US-20110190503-A1 Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase LTA4H, LTC4S, LTB4R2 ALDH1A1 859/4885HSD17B10 664/4885NPC1 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.